The European Medicines Agency has recommended the authorisation of a new veterinary vaccine targeting lumpy skin disease in cattle, advancing the product to the final stage of European Union regulatory approval.

The agency's Committee for Medicinal Products for Veterinary Use (CVMP) adopted the positive opinion. Under the EU veterinary medicines regulation, the CVMP evaluates applications for new products and issues an opinion that the European Commission then translates into a formal marketing authorisation decision.

Lumpy skin disease is a transboundary viral infection of cattle caused by lumpy skin disease virus (LSDV), a member of the Capripoxvirus genus that also includes sheep pox and goat pox viruses. The disease produces biphasic fever, enlarged superficial lymph nodes, and the characteristic skin nodules that give the condition its name. Clinical signs include lacrimation, nasal discharge, and oral lesions.

Economic losses in outbreaks come from reduced milk yield, hide damage, mastitis, orchitis, abortion, and mortality that typically ranges between 1 and 5 percent in naive populations, with morbidity often exceeding 40 percent. The disease is not zoonotic, but it is notifiable across the EU.

Vectors spread LSDV mechanically. Biting flies — particularly Stomoxys species — and certain mosquitoes carry the virus between cattle, which complicates regional control because vector populations respond to climate and seasonal conditions. The virus can also transmit through contaminated equipment and milk.

The EU experienced LSDV introductions in 2015 and 2016, with Greece and Bulgaria recording outbreaks that prompted mass emergency vaccination campaigns using homologous live-attenuated vaccines sourced from third-country manufacturers. The episodes reinforced the EU's interest in licensed, domestically authorised alternatives.

What does the opinion change at the exam table and in the barn?

A licensed EU-authorised LSD vaccine changes the food-animal preventive-medicine conversation in several ways. Cattle practitioners and herd-health veterinarians gain a regulatory-vetted immunological tool with a defined label, withdrawal periods, and pharmacovigilance framework. National chief veterinary officers gain a product they can stockpile or deploy under standard vaccination programmes rather than relying on emergency derogations.

Companion-animal practice sees no direct impact: lumpy skin disease affects cattle, not dogs or cats. Public-health implications are likewise limited because LSDV does not infect humans, although trade and movement-control measures can affect beef and dairy supply chains during outbreaks.

For the EU cattle sector specifically, the most immediate benefit is operational: a centrally authorised product moves freely across member states without the current patchwork of national import licences for non-authorised vaccines.

What's still pending

EMA has not yet disclosed the identity of the manufacturer, the vaccine strain, or specific efficacy data in the announcement. Standard agency practice is to release the full CVMP opinion, including the product name, target species indications, dosage, and onset and duration of immunity, on its website following adoption.

The European Commission now considers the CVMP opinion. Veterinary practitioners should expect a published summary of product characteristics, including withdrawal-period information, after the Commission's formal authorisation decision. Industry observers are watching which platform the authorised product uses — homologous live-attenuated, inactivated, or recombinant — each with different implications for differentiation from field virus, duration of immunity, and use in pregnant animals.

The CVMP's positive opinion brings a regulated European option closer to practising veterinarians working in or trading with regions where lumpy skin disease remains an active and expanding threat.